{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T16:11:40Z","timestamp":1794845500497,"version":"4.9.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universidade de Lisboa","id":[{"id":"https:\/\/ror.org\/01c27hj86","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Destructive thyroiditis is among the most frequent endocrine adverse events of immune checkpoint inhibitors (ICIs). Most reports focus on thyroid dysfunction; less is known about how ICI-induced destructive thyroiditis may remodel thyroid architecture and alter pre-existing nodular disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient findings<\/jats:title>\n                    <jats:p>A 56-year-old woman with a previously documented high-risk thyroid nodule (13 mm, EU-TIRADS 5) was diagnosed with triple-negative breast cancer and started on neoadjuvant therapy including pembrolizumab. Several months into therapy, pre-operative routine testing revealed de novo asymptomatic overt primary hypothyroidism (TSH 123 mIU\/L, fT4 0.14 ng\/dL), leading to postponement of breast surgery. Levothyroxine was initiated (100 \u00b5g\/day), normalizing fT4 within 2 weeks and allowing surgery to proceed, while TSH remained markedly elevated. Thyroid autoantibodies were negative; ICI-induced destructive thyroiditis was presumed. Follow-up ultrasound, performed for planned fine-needle aspiration of the EU-TIRADS 5 nodule, showed a markedly atrophic thyroid gland with no residual suspicious nodules, with the previously documented high-risk nodule no longer detectable. These changes were interpreted as sequelae of destructive thyroiditis. The patient remains asymptomatic on stable levothyroxine replacement, with controlled hypothyroidism, and no breast cancer recurrence at last follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This case highlights that ICI-induced destructive thyroiditis can not only cause severe hypothyroidism but also dramatically remodel thyroid morphology, including regression of an EU-TIRADS 5 nodule. It also illustrates a real-world perioperative dilemma, namely, whether normal fT4, despite very high TSH, is sufficient to proceed with major surgery. Finally, it raises questions about optimal follow-up when a suspicious nodule vanishes following ICI-related thyroiditis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s42000-026-00789-w","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T18:54:38Z","timestamp":1779130478000},"page":"809-815","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Vanishing high-risk thyroid nodule following pembrolizumab-induced destructive thyroiditis: case report and focused literature review"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3841-1493","authenticated-orcid":false,"given":"Marta","family":"Vaz Lopes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Vicente","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Peixe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"de Grin\u00e9 Severino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Raquel","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ema","family":"Lacerda Nobre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"789_CR1","doi-asserted-by":"publisher","first-page":"1584675","DOI":"10.3389\/fendo.2025.1584675","volume":"16","author":"X Mao","year":"2025","unstructured":"Mao X, Mao C, Liu J, Wang X, Mao Y (2025) Immune checkpoint inhibitor-induced thyroiditis and its potential mechanisms. Front Endocrinol (Lausanne) 16:1584675. https:\/\/doi.org\/10.3389\/fendo.2025.1584675","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"789_CR2","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ando.2023.03.005","volume":"84","author":"F Illouz","year":"2023","unstructured":"Illouz F, Briet C, Rodien P (2023) Immune checkpoint inhibitor-related thyroid dysfunction. Ann Endocrinol (Paris) 84(3):346\u2013350. https:\/\/doi.org\/10.1016\/j.ando.2023.03.005","journal-title":"Ann Endocrinol (Paris)"},{"issue":"1","key":"789_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s12020-024-03718-2","volume":"85","author":"D Karaviti","year":"2024","unstructured":"Karaviti D, Kani ER, Karaviti E, Gerontiti E, Michalopoulou O, Stefanaki K et al (2024) Thyroid disorders induced by immune checkpoint inhibitors. Endocrine 85(1):67\u201379. https:\/\/doi.org\/10.1007\/s12020-024-03718-2","journal-title":"Endocrine"},{"issue":"11","key":"789_CR4","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1210\/clinem\/dgad260","volume":"108","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Jiao X, Lai X (2023) Clinical Characters and Influence Factors of Immune Checkpoint Inhibitor-related Thyroid Dysfunction. J Clin Endocrinol Metab 108(11):2916\u20132923. https:\/\/doi.org\/10.1210\/clinem\/dgad260","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"789_CR5","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1159\/000478927","volume":"6","author":"G Russ","year":"2017","unstructured":"Russ G, Bonnema SJ, Erdogan MF, Durante C, Ngu R, Leenhardt L (2017) European Thyroid Association Guidelines for Ultrasound Malignancy Risk Stratification of Thyroid Nodules in Adults: The EU-TIRADS. Eur Thyroid J 6(5):225\u2013237. https:\/\/doi.org\/10.1159\/000478927","journal-title":"Eur Thyroid J"},{"key":"789_CR6","doi-asserted-by":"publisher","unstructured":"Tessler FN, Middleton WD, Grant EG, Hoang JK, Berland LL, Teefey SA et al (2017) White Paper of the ACR TI-RADS Committee. J Am Coll Radiol 14(5):587\u2013595 ACR Thyroid Imaging, Reporting and Data System (TI-RADS). https:\/\/doi.org\/10.1016\/j.jacr.2017.01.046","DOI":"10.1016\/j.jacr.2017.01.046"},{"issue":"8","key":"789_CR7","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1210\/jc.2017-00448","volume":"102","author":"DA Delivanis","year":"2017","unstructured":"Delivanis DA, Gustafson MP, Bornschlegl S, Merten MM, Kottschade L, Withers S et al (2017) Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms. J Clin Endocrinol Metab 102(8):2770\u20132780. https:\/\/doi.org\/10.1210\/jc.2017-00448","journal-title":"J Clin Endocrinol Metab"},{"key":"789_CR8","doi-asserted-by":"publisher","first-page":"113949","DOI":"10.1016\/j.ejca.2024.113949","volume":"202","author":"OJ Kennedy","year":"2024","unstructured":"Kennedy OJ, Ali N, Lee R, Monaghan P, Adam S, Cooksley T et al (2024) Thyroid dysfunction after immune checkpoint inhibitors in a single-centre UK pan-cancer cohort: A retrospective study. Eur J Cancer 202:113949. https:\/\/doi.org\/10.1016\/j.ejca.2024.113949","journal-title":"Eur J Cancer"},{"key":"789_CR9","doi-asserted-by":"publisher","first-page":"606056","DOI":"10.3389\/fimmu.2021.606056","volume":"12","author":"J Jabkowski","year":"2021","unstructured":"Jabkowski J, Loidl A, Auinger B, Kehrer H, Sepp N, Pichler R (2021) Pembrolizumab-Induced Thyroiditis Shows PD-L1 Expressing Histiocytes and Infiltrating T Cells in Thyroid Tissue - A Case Report. Front Immunol 12:606056. https:\/\/doi.org\/10.3389\/fimmu.2021.606056","journal-title":"Front Immunol"},{"issue":"5","key":"789_CR10","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.aace.2023.05.009","volume":"9","author":"DH Chen","year":"2023","unstructured":"Chen DH, Lenz HJ, Lechner MG, Angell TE (2023) Reduced Tumor Size of Untreated Papillary Thyroid Carcinoma After Immune Checkpoint Inhibitor-Induced Thyroiditis. AACE Clin Case Rep 9(5):162\u2013165. https:\/\/doi.org\/10.1016\/j.aace.2023.05.009","journal-title":"AACE Clin Case Rep"},{"issue":"3","key":"789_CR11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1159\/000506107","volume":"9","author":"A Palermo","year":"2020","unstructured":"Palermo A, Napolitano A, Maggi D, Naciu AM, Tabacco G, Manfrini S et al (2020) Regression of Papillary Thyroid Cancer during Nivolumab for Renal Cell Cancer. Eur Thyroid J 9(3):157\u2013161. https:\/\/doi.org\/10.1159\/000506107","journal-title":"Eur Thyroid J"},{"key":"789_CR12","doi-asserted-by":"publisher","first-page":"899575","DOI":"10.3389\/fendo.2022.899575","volume":"13","author":"Q Chen","year":"2022","unstructured":"Chen Q, Lin M, Wu S (2022) Validating and Comparing C-TIRADS, K-TIRADS and ACR-TIRADS in Stratifying the Malignancy Risk of Thyroid Nodules. Front Endocrinol (Lausanne) 13:899575. https:\/\/doi.org\/10.3389\/fendo.2022.899575","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"789_CR13","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.3390\/diagnostics15081015","volume":"15","author":"E Tobcu","year":"2025","unstructured":"Tobcu E, Karava\u015f E, Y\u0131lmaz GT, Top\u00e7u B (2025) Comparison of K-TIRADS, EU-TIRADS and ACR-TIRADS Guidelines for Malignancy Risk Determination of Thyroid Nodules. Diagnostics (Basel) 15(8):1015. https:\/\/doi.org\/10.3390\/diagnostics15081015","journal-title":"Diagnostics (Basel)"},{"key":"789_CR14","doi-asserted-by":"publisher","first-page":"117863291668967","DOI":"10.1177\/1178632916689677","volume":"10","author":"MR Palace","year":"2017","unstructured":"Palace MR (2017) Perioperative Management of Thyroid Dysfunction. Health Serv Insights 10:1178632916689677. https:\/\/doi.org\/10.1177\/1178632916689677","journal-title":"Health Serv Insights"},{"issue":"5","key":"789_CR15","doi-asserted-by":"publisher","first-page":"428","DOI":"10.4103\/ijem.ijem_273_22","volume":"26","author":"B Malhotra","year":"2022","unstructured":"Malhotra B, Bhadada SK (2022) Perioperative Management for Non-Thyroidal Surgery in Thyroid Dysfunction. Indian J Endocrinol Metab 26(5):428\u2013434. https:\/\/doi.org\/10.4103\/ijem.ijem_273_22","journal-title":"Indian J Endocrinol Metab"},{"issue":"12","key":"789_CR16","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1016\/j.mayocp.2020.05.004","volume":"95","author":"CP Himes","year":"2020","unstructured":"Himes CP, Ganesh R, Wight EC, Simha V, Liebow M (2020) Perioperative Evaluation and Management of Endocrine Disorders. Mayo Clin Proc 95(12):2760\u20132774. https:\/\/doi.org\/10.1016\/j.mayocp.2020.05.004","journal-title":"Mayo Clin Proc"},{"issue":"18","key":"789_CR17","doi-asserted-by":"publisher","first-page":"16501","DOI":"10.1007\/s00432-023-05364-z","volume":"149","author":"Y Lu","year":"2023","unstructured":"Lu Y, Li Q, Xu L, Zheng Y, Wang Y, Liu Y et al (2023) Thyroid dysfunction induced by anti-PD\u20131 therapy is associated with a better progression-free survival in patients with advanced carcinoma. J Cancer Res Clin Oncol 149(18):16501\u201316510. https:\/\/doi.org\/10.1007\/s00432-023-05364-z","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"789_CR18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.21873\/cdp","volume":"2","author":"MG Chilelli","year":"2022","unstructured":"Chilelli MG, Signorelli C, Giron Berrios JR, Onorato A, Nelli F, Fabbri MA et al (2022) Immune-related Thyroid Dysfunction (irTD) in Non-small Cell Lung Cancer (NSCLC) Correlates With Response and Survival. Cancer Diagn Progn 2(1):55\u201363. https:\/\/doi.org\/10.21873\/cdp","journal-title":"Cancer Diagn Progn"},{"key":"789_CR19","doi-asserted-by":"publisher","first-page":"1010279","DOI":"10.3389\/fendo.2022.1010279","volume":"13","author":"A Chera","year":"2022","unstructured":"Chera A, Stancu AL, Bucur O (2022) Thyroid-related adverse events induced by immune checkpoint inhibitors. Front Endocrinol (Lausanne) 13:1010279. https:\/\/doi.org\/10.3389\/fendo.2022.1010279","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"789_CR20","doi-asserted-by":"publisher","first-page":"e240120","DOI":"10.1530\/ERC-24-0120","volume":"31","author":"M Villanova","year":"2024","unstructured":"Villanova M, Tolaney SM, Min L (2024) Association between pembrolizumab-related thyroid adverse events and outcomes in early-stage triple-negative breast cancer patients. Endocr Relat Cancer 31(11):e240120. https:\/\/doi.org\/10.1530\/ERC-24-0120","journal-title":"Endocr Relat Cancer"}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-026-00789-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s42000-026-00789-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-026-00789-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T14:32:27Z","timestamp":1794839547000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s42000-026-00789-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["789"],"URL":"https:\/\/doi.org\/10.1007\/s42000-026-00789-w","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"value":"1109-3099","type":"print"},{"value":"2520-8721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"20 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This report was conducted in accordance with the principles of the Declaration of Helsinki. According to the policy of our institutional ethics committee, single-patient case reports without identifiable data are exempt from formal review. Written informed consent for publication of clinical data was obtained from the patient.","order":1,"name":"Ethics","label":"Ethics statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}